Cat. No. 5443
Chemical Name: 5-[4-(4-Cyano-1-butyn-1-yl)phenyl]-
Biological ActivityHigh affinity and selective CB1 antagonist (Ki = 3.3 nM). Exhibits >100-fold selectivity for CB1 over CB2 receptors. Improves glucose homeostasis, reverses hepatic steatosis and reduces body weight in diet-induced obese mice. Orally available and non-brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Bowles et al (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc.Natl.Acad.Sci.U.S.A. 112 285. PMID: 25535367.
Tam et al (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J.Clin.Invest. 120 2953. PMID: 20664173.
If you know of a relevant reference for AM 6545 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AM 6545 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AM 6545, supplier, AM6545, CB1, receptors, antagonists, high, affinity, selective, obesity, lipids, glucose, Tocris Bioscience, CB1 Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective CB2 partial agonist; orally biovailable
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.